Trial record 1 of 6 for:    pazopanib GIST
Previous Study | Return to List | Next Study

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Centre Leon Berard
ClinicalTrials.gov Identifier:
NCT01323400
First received: March 10, 2011
Last updated: August 1, 2014
Last verified: December 2012

March 10, 2011
August 1, 2014
March 2011
April 2014   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: Within 16 months after the first inclusion, from the date of randomisation until the date of the first documented progression or death from any cause ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01323400 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: Within 16 months after the first inclusion, from the date of randomisation until the date of death from any cause ] [ Designated as safety issue: No ]
  • Objective tumour response rate (RECIST v.1.1) at 4 months [ Time Frame: 4 months after randomisation ] [ Designated as safety issue: No ]
  • Best response (RECIST v.1.1) obtained during the study [ Time Frame: Within 16 months after the first inclusion ] [ Designated as safety issue: No ]
  • Tolerance profile (NCI-CTCAE v.4.0) [ Time Frame: Within 16 months after the first inclusion ] [ Designated as safety issue: Yes ]
  • Pattern of progression-free survival in the different molecular subtypes [ Time Frame: Within 16 months after the first inclusion, from the date of randomisation until the date of the first documented progression or death from any cause ] [ Designated as safety issue: No ]
  • Intra and inter-patient variability of the Cmin of pazopanib [ Time Frame: After 4 weeks, 10 weeks, 16 weeks of pazopanib treatment and at time of progression ] [ Designated as safety issue: No ]
  • Progression-free survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression [ Time Frame: Within 16 months after the first inclusion, from the date of the first pazopanib administration until the date of the first documented progression or death from any cause ] [ Designated as safety issue: No ]
  • Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression [ Time Frame: Within 16 months after the first inclusion, from the date of the first pazopanib administration until the date of death from any cause ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib

The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib. This is a phase II, randomized, multicentre study.

Complete resection, with or without associated anticancer therapy, is the standard treatment of GIST. Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors (TKI-imatinib, sunitinib...), the vast majority of patients will develop secondary resistance to these agents. The therapeutic options for patients with advanced GIST with resistance (or intolerance) to imatinib and sunitinib remain very limited. Some new molecules are currently being evaluated in patients with metastatic or locally advanced - imatinib-resistant disease. Nilotinib, for instance, has been evaluated in phase I/II trials and compassionate use programs with a median progression-free survival (PFS) close to 3 months and a median overall survival close to 8.5 months. A phase III trial comparing nilotinib vs. best supportive care (BSC) +/- imatinib or sunitinib (investigators choice) has just been completed and results are pending. Another molecule, Sorafenib, has been evaluated in 4th line treatment in compassionate use studies, with a median PFS close to 5 months and a median overall survival of 10-13 months. There are currently no recognized standard options after failure of 2nd line treatment, and the recently updated guidelines from the NCCN or ESMO (2009) suggest the possible reintroduction of TKI in an attempt to control the progression of sensitive cell clones.

Pazopanib is a broad spectrum TKI targeting KIT, PDGFR and VEGFR which has been tested in phase II trials in advanced sarcomas and has demonstrated promising antitumor activity. Whether pazopanib would be useful in patients with GIST is not known.

In the present study, we propose to analyze the antitumor activity of pazopanib in patients with GIST refractory to imatinib and sunitinib. The drug will be tested against BSC in a randomized setting, with possible crossing-over to the no-treatment arm.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
GIST
  • Drug: Pazopanib
    Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
    Other Name: Pazopanib
  • Other: Best supportive care

    Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).

    Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.

    Other Name: Best supportive care
  • Experimental: Pazopanib

    Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.

    Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed.

    Interventions:
    • Drug: Pazopanib
    • Other: Best supportive care
  • Best supportive care
    Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
    Intervention: Other: Best supportive care

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
81
October 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Histologically confirmed, unresectable, metastatic and/or locally advanced GIST.
  3. Progression or intolerance after treatment with at least imatinib (400 mg and 600/800 mg/d) then sunitinib at either 50mg/d on a 4w/6w schedule or 37.5mg/d continuous dosing. Intolerance is defined as documented grade 3 or higher toxicity requiring treatment interruption as documented in patient record.
  4. Measurable disease according to RECIST v1.1.
  5. Performance status ≤ 2 (WHO).
  6. Left Ventricular Ejection Fraction (LVEF) in accordance with local standards.
  7. Adequate organ system functions as defined below:

    • Haematologic parameters

      • Absolute neutrophil count (ANC) ≥ 1.5 G/L
      • Haemoglobin ≥ 9 g/dL
      • Platelets ≥ 100 G/L
      • Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 X upper limit of normal (ULN) NB: Subjects receiving anticoagulation therapy are eligible if INR is stable and within the recommended range.
      • Partial thromboplastin time (PTT) ≤ 1.2 X ULN
    • Hepatic parameters

      • Total bilirubin ≤ 1.5 X ULN
      • AST and ALT ≤ 2.5 X ULN
    • Renal parameters

      • Serum creatinine ≤ 1.5 mg/dL (133 µmol/L) or, if greater than 1.5 mg/dL: calculated creatinine clearance ≥ 50 mL/min
      • Urine Protein to Creatinine ratio (UPC) < 1. If UPC ≥ 1, subjects must have a 24-hour urine protein value <1g to be eligible.
    • Biochemical parameters

      • Kaliemia ≥ 1 X lower limit of normal (LLN)
  8. a) Females of non-childbearing potential (i.e., physiologically incapable of becoming pregnant).

    b) Females of childbearing potential provided that they are not pregnant or lactating, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and who agrees to use adequate contraception.

  9. Affiliation with a health insurance company.
  10. Subjects must provide written informed consent

Exclusion Criteria:

  1. Prior malignant disease (other than GIST) within 3 years prior to entry, with the exception of in situ breast cell carcinoma or in situ carcinoma of the cervix or basocellular carcinoma or spinocellular carcinoma or bladder neoplasm, treated at least 6 months before and with no evidence of relapse.
  2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for patients with previously-treated CNS metastases, who are asymptomatic and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. CNS screening with computed tomography [CT] or magnetic resonance imaging [MRI] is required only if clinically indicated or if the subject has a history of CNS metastases.
  3. Treatment with any of the following anti-cancer therapies:

    • radiation therapy, surgery or tumour embolisation within 14 days prior to the first dose of pazopanib OR
    • chemotherapy, biological therapy or investigational therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib.

    The analgesic radiation therapy is allowed (the irradiated lesions won't be chosen as target lesions during the evaluation)

  4. Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 followed and/or progressing in severity, except alopecia.
  5. Other uncontrolled severe medical conditions.
  6. Presence of uncontrolled infection.
  7. Clinically significant gastrointestinal abnormalities

    • that may increase the risk for gastrointestinal bleeding.
    • that may affect absorption of investigational product.
  8. Poorly controlled hypertension [defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg].

    NB: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions at > 1 hour interval; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be <140/90 mmHg for the subject to be eligible to the study.

  9. History of any cardiovascular pathology within the past 6 months.
  10. Corrected QT interval (QTcB) > 480 msec using Bazett's formula.
  11. History of cerebrovascular accident, including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT), within the past 6 months.

    NB: Subjects with recent DVT treated with therapeutic anti-coagulating agents at least 6 weeks before inclusion are eligible.

  12. Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer (procedures such as catheter placement are not considered to be major).
  13. Evidence of active bleeding or bleeding diathesis.
  14. Haemoptysis within 8 weeks before inclusion.
  15. Platelet transfusion in the past 7 days.
  16. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.
  17. Concomitant bilirubin and AST/ALT elevations above ULN.
  18. Treatment with anti-vitamin K (LMWH are allowed).
  19. Inability or unwillingness to discontinue prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.
  20. Inability to swallow.
  21. Pregnant or lactating woman
  22. Impossibility to comply with protocol constraints
Both
18 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01323400
PAZOGIST
No
Centre Leon Berard
Centre Leon Berard
GlaxoSmithKline
Principal Investigator: Jean-Yves BLAY, MD Centre Léon Bérard, LYON, FRANCE
Centre Leon Berard
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP